The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Stroke, dementia, and late-life depression share 17 modifiable risk factors, a systematic review found. (Journal of Neurology ...

The UCSF luminary and recipient of the prestigious award has played a pivotal part in identifying the cause of multiple sclerosis, leading to a new generation of game-changing therapies.

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.

Two prominent scientists who study multiple sclerosis — Dr. Alberto Ascherio and Dr. Stephen Hauser — are co-winners of a ...

Neuro-immunologist Stephen Hauser , MD, whose maverick thinking transformed the treatment landscape for patients with ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...